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Abstract
Background: Previously we have shown that B cell receptor (BCR) expression and B cell receptor
signaling pathways are important for the basal growth of B lymphoma cells. In particular we have shown
that the activation of Syk, a non-src family protein tyrosine kinase and the mitogen activated protein
kinases (MAPK), ERK and JNK that mediate BCR signals are required for the constitutive growth of B
lymphoma cells. Since src family protein tyrosine kinases (SFKs) like Lyn are known to be needed for the
phosphorylation of BCR co-receptors, Ig-α and Ig-β, we hypothesized that one or more SFKs will be
constitutively activated in B lymphoma cells and may be necessary for B lymphoma growth.
Results: Src kinase activity was found to be constitutively high in many murine and human B lymphoma
cell lines and primary lymphoma samples. The specific pharmacological inhibitors of SFKs, PP1 and PP2
inhibited the proliferation of a number of both murine and human B lymphomas in a dose-dependent
manner. Importantly, dasatinib (BMS-354825), an oral dual BCR-ABL and SFK specific inhibitor inhibited
the growth of B lymphomas in the nanomolar range in vitro and strongly inhibited a mouse lymphoma
growth in vivo. Among the SFKs, Lyn is predominantly phosphorylated and Lyn-specific small interfering
RNA inhibited the growth of B lymphomas, supporting an important role for Lyn in B lymphoma growth.
Suppression of SFK activity blocks BCR mediated signaling pathways. PMA or CpG can partially reverse
the growth inhibition induced by SFK inhibition. Although blocking SFK activity inhibited the growth of a
number of B lymphomas, some lymphomas such as SudHL-4, SudHL-6, OCI-Ly3 and OCI-Ly10 are more
resistant due to an increased expression of the anti-apoptotic proteins Bcl-2 and Bcl-xL.
Conclusions: These studies further support our concept that BCR signaling pathways are important for
the continued growth of established B lymphoma cells. Some of the intermediates in this BCR pathway are
potential immunotherapeutic targets. In particular, inhibition of SFK activity alone or in synergy with
inhibition of the prosurvival Bcl-2 proteins holds promise in developing more effective treatments for B
lymphoma patients.
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Introduction
Non-Hodgkin lymphoma (NHL) is the fifth most com-
mon cancer in the United States. About 90% NHLs are of
B-cell origin. Diffuse large B-cell lymphoma (DLBCL) (30-
40%) and follicular lymphoma (20%) are the two most
common NHLs [1]. The genetic hallmarks of B-cell lym-
phomas are reciprocal chromosomal translocations
involving one of the Ig loci and a proto-oncogene, such as
BCL2, BCL6 or c-Myc [1,2]. In addition to these transloca-
tion events, B lymphoma cells maintain dependence on B
cell surface receptor (BCR) signaling for survival and
growth [3].
B-cell lymphomas arise during various stages of B cell
development. B-cell precursors in bone marrow differen-
tiate into mature naïve B cells and leave the bone marrow
only after a B-cell precursor successfully rearranges Ig H
and L chains and expresses a functional BCR. During
development, B cells undergo stringent selection for
expression of the appropriate BCR. Expression of BCR is
even required for the survival of mature resting B cells
because ablation of BCR expression in mice leads to apop-
tosis of BCR-negative B cells [4]. B-cell lymphomas appear
to be also under selective pressure to express BCR [1].
First, most B-cell lymphomas still express surface BCR.
Second, translocations into the Ig-loci are virtually always
found on the non-productively rearranged Ig loci. Third,
treatment of patients who had follicular lymphoma with
anti-idiotypic antibodies did not result in the emergence
of BCR-negative lymphoma variants. Fourth, gene expres-
sion analysis demonstrated that BCR signaling pathways
are elevated in a number of DLBCL that don't respond
well to chemotherapy [5,6]. Finally, the siRNAs targeting
Igα and Igβ caused suppression of B lymphoma growth
[3]. These data suggested that the BCR complex provides
survival signals for B lymphoma cells. Moreover, it was
shown that proteins containing immunoreceptor tyro-
sine-based activation motifs (ITAM) are sufficient to cause
transformation. A recombinant protein consisting of
ITAM containing cytoplasmic regions of Igα and Igβ of
BCR complex caused transformation of mammary epithe-
lial cells and fibroblasts [7]. The Kaposi sarcoma-associ-
ated herpes virus K1 protein bearing ITAM motif induced
plasmablastic lymphomas in K1 transgenic mice [8]. The
ITAM containing proteins induced transformation pre-
sumably by acting as a scaffold for downstream media-
tors.
For B cell activation, BCR engagement by antigen leads to
activation of Src kinase Lyn, which phosphorylates the
ITAM motifs of Igα and Igβ of the BCR complex. The
phosphorylated ITAM motifs recruit the Syk kinase to
mediate multiple downstream signals to instruct normal
B cells to make crucial cell-fate decisions in cell differenti-
ation [9,10]. Since Lyn is also responsible for phosphor-
ylating several inhibitory (ITIM-containing) receptors in B
cells and myeloid cells, it was discovered to have a dual
role acting both as a positive and a negative signaling mol-
ecule [11]. However, due to the ability of other SFKs to
substitute for Lyn activity in B cells, BCR signaling is not
interrupted in the complete absence of Lyn [12-15]. For T
cell activation, the counterpart of Lyn is Src kinase Lck,
which phosphorylates the ITAM motifs of CD3 of the TCR
complex. In both cases, Src kinases are essential for recep-
tor mediated early signaling events required for B (or T)
cell survival and activation. Syk has been found to be con-
stitutively active in B lymphomas and inhibitors of Syk
reduce growth of B lymphoma cells [16,17].
SFKs are non-receptor protein tyrosine kinases with nine
known members, Src, Yes, Fyn, Lyn, Lck, Hck, Fgr, Blk and
Yrk. In addition to their role in mediating immune
response as mentioned above for Lyn and Lck, SFKs are
also involved in the control of cellular processes such as
cell survival, proliferation, differentiation, phagocytosis,
angiogenesis, adhesion, motility [11,18-22]. Each SFK has
a unique N-terminal domain followed by three conserved
Src homology domains: SH3, SH2 and SH1. All SFKs are
myristoylated at the N terminus, which targets them to the
cell membrane. They are regulated by phosphorylation at
two critical tyrosines with opposing effects. Phosphoryla-
tion at the C-terminal tyrosine (Y527 for c-Src) by C-ter-
minal kinase (Csk) suppresses its activity whereas
phosphorylation of the tyrosine (Y416 for c-Src) in the
activation loop of the kinase domain (SH1) up regulates
its activity.
c-Src, the archetypal member of SFKs, is implicated in a
large number of human cancers including colorectal,
hepatocellular, pancreatic, breast, ovarian and lung can-
cers [18,23]. Blk is preferentially expressed in B cell line-
age and involved in the early development of B cells.
Expression of constitutively active Src kinase Blk (Y495F)
in B and T lymphoid compartment induces transforma-
tion of specific B and T cell progenitor cells into lympho-
mas [24,25]. Studies show that Src kinase Lyn is the
predominant cellular Src activity in glioblastoma tumor
cells [26] and chronic lymphocytic leukemia B cells [27]
and promotes the malignant phenotype in these tumors.
Lyn also plays an important role for chronic myelogenous
leukemia (CML) blast crisis cells and Lyn siRNA induces
apoptosis of drug (Gleevec) resistant BCR-ABL1(+) cells
[28]. In another study, at least two SFKs were required for
efficient induction of B-lymphoid leukemia by BCR-Abl
[29].
Together with the data on the importance of SFKs in
leukemias and our finding that BCR signaling is required
for basal B lymphoma growth, we hypothesized that Src
kinase activity, especially Lyn activity, is elevated in B lym-
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phoma cells and that the elevated Src kinase activity pro-
motes B lymphoma growth. Despite some studies with
cell lines [30], there is little information about Lyn activa-
tion in primary lymphoma cells, its role in BCR depend-
ent lymphoma growth, and its importance for in vivo B
lymphoma growth. Consistent with this hypothesis, we
observed constitutively active Src kinase activity in a
number of primary B lymphoma cells and lymphoma cell
lines but not in normal B cells. DLBCLs were used to eval-
uate the importance of SFK for B lymphoma growth. Spe-
cific pharmacological inhibitors of SFK (PP1, PP2 and
dasatinib) induced a dose dependent inhibition of B lym-
phoma cell growth due to G1-S arrest. dasatinib strongly
inhibited the BKS-2 lymphoma growth in vivo in a mouse
lymphoma model. Although other members of SFK were
expressed variably in lymphoma cells, Lyn is the predom-
inant kinase that is constitutively phosphorylated and
appears to be critical for B lymphoma growth. We demon-
strated that inhibition of SFK reduced BCR signaling.
Materials and methods
Reagents
PP1, PP2, and PP3 were obtained from BIOMOL Interna-
tional, L.P. (Plymouth Meeting, PA). dasatinib was
obtained from the University of Kentucky Hospital. Phos-
pho-specific antibodies against Src(Tyr416), Lyn(Tyr507),
JNKs(Thr183/Tyr185), CD19(Tyr513), ERKs(Thr202/
Tyr204) and AKT(Ser473), phospho-Tyrosine (P-Tyr100,
biotinylated) were obtained from Cell Signaling Technol-
ogies (Beverly, MA). Antibodies against total Src, Fgr, Fyn,
Hck, Yes, AKT were also obtained from Cell Signaling
Technologies (Beverly, MA). Antibodies against total Lck,
Lyn, Blk, Igα, cyclin D2, Egr-1(C-19), ERK1, Bcl-XL and
Bcl-2 were obtained from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA). Monoclonal anti-β-actin antibody was
obtained from Sigma-Aldrich (St. Louis, MO). The siRNA
against human Lyn and control siRNA were obtained
from Dharmacon, Inc (Lafayette, CO). The phospho-
rothioate-modified CpG oligonucleotides (ODN) 3Db as
described by Krieg et al. [31] was obtained from the
Regional DNA Synthesis Laboratory (Calgary, Canada).
Cells and Mice
Female CBA/N (Xid) mice were purchased from The Jack-
son Laboratory (Bar Harbor, ME). Mice were housed
under specific pathogen-free conditions in micro-isolator
cages under the American Association for Laboratory Ani-
mal Accreditation and Certification approved protocol. B
lymphoma cell lines of both murine and human origins
were described previously [3]. Primary human B lym-
phoma cells were obtained from anonymized discarded
flow cytometry samples under an IRB exemption proto-
col. Human peripheral blood lymphocytes (PBLs) were
obtained from discarded samples generated by the Cen-
tral Kentucky Blood Center during RBC enrichment.
Mononuclear cells were obtained after subjecting PBLs to
centrifugation on a Ficoll-Hypaque cushion [32] and then
B cells were enriched with CD19 microbeads (Miltenyi
Bergisch Gladbach, Germany) using the manufacturer's
protocol. The isolation and characterization of BKS-2 and
host T cell depletion have been described previously
[33,34]. BKS-2 cells were grown in female CBA/N (Xid)
mice as splenic tumors by intravenous injection. These
cells attained maximal growth (2-6 × 108 cells per mouse
spleen) in 7-10 days and were collected for experimental
use at this stage.
Western Blot Analysis and Immunoprecipitation
Various B lymphoma cells (5 × 106) with or without treat-
ments were cultured at 1 × 106/ml in 6-well plates (Cos-
tar) for the indicated time. Cell pellets were lysed in a
buffer with 1% Triton X-100 and protease inhibitors and
processed for Western blots as described [35-37]. The
blots were developed with Pico chemiluminescence sub-
strate (Pierce) and exposed to Kodak X-Omat films, or
analyzed by an Eastman Kodak Image Station 2000RT.
For re-probing, membranes were stripped using a solution
containing 62.5 mM Tris-HCl, 2% SDS, and 100 mM β-
mercaptoethanol at 62°C for 10 min. For immunoprecip-
itation, the cell lysates were pre-cleared by incubation
with 50 μl protein G beads (50% v/v) at 4°C for 1 hr. The
cleared lysate was incubated with 2-5 μg of antibody for 2
hrs at 4°C. The immune complex was isolated on protein
G beads (50% v/v) and was analyzed by Western blot.
Densitometry for bands on Western blots was quantified
using the Gel Analysis method of the ImageJ program
according to its documentation http://rsb.info.nih.gov/ij/
[38].
Transfection of siRNA into B Lymphoma Cells
The sequence of Lyn-specific siRNA used in this study was
obtained from a successful previous attempt to repress
Lyn protein. The sense and antisense sequences of human
Lyn-specific siRNA were 5'-AGACUCAACCAGUAC-
GUAAUU-3' and 5'-PUUACGUACUGGUUGAGUCUUU-
3', respectively [28]. The non-specific control siRNA with
Cat# D-001206-01-20 was used. Lyn specific siRNA or the
control siRNA was introduced into B lymphoma cells by
electroporation. 5-8 × 106 lymphoma cells were washed,
resuspended in cold Opti-MEM I reduced serum media
(GIBCO) mixed with 500 nM of control or Lyn specific
siRNA and electroporated at 260 mV, 960 microfarads,
and 200 ohms. The transfection efficiency for SudHL-4
and -6 cell lines was determined to be about 70%, based
on co-transfection with a GFP expressing plasmid. One
day post-electroporation, lymphoma cells were counted,
and an equal number of cells with the indicated treatment
were used to set up the proliferation assay as described.
Cell Proliferation and Cell Cycle Assays
Lymphoma cells (2-3 × 104/well) were cultured in 96-well
flat-bottom microtiter plates (Costar, Cambridge, MA) in
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200 μl of media with 10% FCS. The cells were pulsed with
1 μCi of [3H] thymidine (PerkinElmer Life Sciences) dur-
ing the last 4 hrs of the 48 hrs culture period. The cells
were harvested and the radionucleotide incorporation
was measured with a Matrix 96 β-radiation counter
(Hewlett-Packard, Downers Grove, IL). Results are pre-
sented as the means ± S.E. of triplicate cultures. The per-
cent control response is defined as (cpm in the treated
group/cpm in the untreated group) × 100. To determine
the IC50 a linear regression was plotted between points
near 50% inhibition and the resulting equation was used
to determine the dose that caused 50% growth inhibition.
The cell cycle was analyzed using propidium iodide (PI).
B lymphoma cells (0.5 × 106/ml) were treated with vary-
ing doses of PP1 or PP2 and then fixed in 70% (v/v) eth-
anol for at least 1 h at 4°C, after which cells were
incubated in a mixture of 1 μg/ml PI (Sigma-Aldrich) and
25 μg/ml RNase A (Sigma-Aldrich) at 37°C for 30 min.
The level of PI fluorescence was measured with a MoFlo
flow cytometer (DakoCytomation). Cell populations at
subG1, G1, S, G2/M phase were calculated using the pro-
gram ModFit.
Cell Apoptosis Analysis
B lymphoma cells were treated with various doses of
inhibitors for one to three days and stained with Annexin
V (FITC or APC) (BD Pharmingen) at room temperature
for 15 min in the dark. Then 3 μl of PI solution (0.5 μg/
ml) was added and samples were analyzed by flow cytom-
etry within one hour.
In vivo tumor inhibition study
2 month old female CBA/N (Xid) mice were injected
intravenously with 7 × 106 BKS-2 B lymphoma cells on
day 0. From day 1, mice were injected intraperitoneally
either with 1 mg/kg body weight dasatinib in 1 × PBS with
10% DMSO or 200 μl of vehicle (1 × PBS, 10% DMSO)
everyday for 14 days. Mice were sacrificed afterwards and
spleens were removed to count for total number of splenic
tumor cells.
Results
SFKs are constitutively activated in a number of primary B 
lymphomas and B lymphoma cell lines
Since SFKs play a key role in B-lymphoid transformation
[39] we examined the levels of active SFKs present in B
lymphoma lines, primary lymphoma tumor samples, and
normal B cells (Fig. 1A). Phospho-Src (Y416) antibody
specifically detects phosphorylation of tyrosine 416 at the
activation loop of Src, an indication of active form of Src.
It also cross-reacts with other Src family protein tyrosine
kinases phosphorylated at equivalent position. Compared
to normal murine splenic B cells, the level of active SFK
was significantly elevated in murine lymphoma cell lines
(BKS-2 and CH12) and two murine primary lymphomas
from EμMyc transgenic mice (#3 and #4). The level of
active SFK was also significantly elevated in DLBCL cell
lines (SudHL6, OCI-Ly3 and OCI-Ly10), primary lym-
phoma samples, and EBV transformed B cells over normal
human peripheral blood B cells (Fig. 1A).
Blocking SFK activity suppresses B lymphoma cell growth
To block SFK activity, lymphoma cells were treated in
vitro with the widely used synthetic pyrazolopyrimidine
compounds, PP1 and PP2 or the inactive analogue, PP3
[40]. Treatment with PP2 potently inhibited the growth of
BKS-2 and SudHL-4 cells while the inactive analog PP3
had no effect (Fig. 1B). PP2 also inhibited several other B
lymphoma cell lines of human and murine origin (Table
1). A similar pattern was also observed for another SFK
inhibitor, PP1 with slightly lower potency for some of the
cell lines (Table 1). The IC50 of PP1 and PP2 for most cell
lines were in the micromolar range. OCI-Ly3 had the
highest IC50 for PP1 and PP2 compared with other cell
lines, which correlated well with the highest level of phos-
pho-SFK in the OCI-Ly3 cell line.
Dasatinib (BMS-354825) is an oral dual BCR/ABL and
SFK inhibitor approved for use in patients with CML and
Philadelphia chromosome-positive acute lymphoblastic
leukemia [41-44]. Dasatinib very potently inhibited the
growth of a number of B lymphoma cells. The IC50 of
dasatinib for most cell lines was at nanomolar concentra-
tions, one thousand fold less than the PP1 or PP2 inhibi-
tors. In general, murine cell lines BKS-2, WEHI-231, CH12
were inhibited by lower doses of dasatinib than the
human cell lines SudHL-6, OCI-Ly10 and SudHL-4 (Fig.
1C &1D). The OCI-Ly3 cell line required much higher
dose of dasatinib to inhibit its growth, consistent with its
highest level of phospho-SFK (Fig. 1A and Table 1). There
was a small increase in growth of B lymphoma cells at low
doses of dasatinib (Fig. 1C) and PP1 (data not shown).
This could be due to a negative role for SFK in B lym-
phoma growth. Lyn is well documented to have both pos-
itive and negative roles in B cell proliferation and in
myeloid cells [11,19]. The negative role of Lyn is in part
due to its ability to phosphorylate tyrosine phosphatases,
such as SHP-1 and SHIP-1 [45-47]. The enhancement seen
at low doses of dasatinib may also relate to the ability of
dasatinib to bind CSK, a negative regulator of SFK [48].
Blocking SFK activity induces G1/S growth arrest 
accompanied by apoptosis of B lymphomas
Treatment with the SFK inhibitors PP2 or dasatinib
induced predominantly G1 arrest in both BKS-2 and
SudHL-4 cell lines in comparison to cells treated with the
inactive analogue PP3 (Fig. 2A &2B) or the vehicle (data
not shown), suggesting that SFK activity is needed for lym-
phoma cells to progress from G1 to S phase. PP2 had a
similar effect on the proportion of cells in S phase in
WEHI-231 (from 52.8% to 13.7%) and SUDHL-6 (from
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B lymphomas have high SFK activity as compared to normal B cellsFigure 1
B lymphomas have high SFK activity as compared to normal B cells. (Panel A) The top row of blots is of mouse and 
the bottom row is of human B cells. SudHL-4 and 6, Ly3 and 10, and human primary lymphoma #1 are diffuse large B cell lym-
phomas while the murine primary lymphomas were from EμMyc transgenic mice. Human primary lymphomas #2 & 3 are small 
cell lymphomas. The cell lysates were first probed for phospho-SFK with p-Src (Y416) antibody, then stripped and re-probed 
for β-actin as a loading control. The ODs for the p-SFK bands were normalized to the corresponding β-actin bands. The ratios 
are provided under each lane and are depicted as a fold change over normal cells (i.e. murine lymphomas as a ratio to murine 
splenic B cells and human lymphomas as a ratio to PB B cells). (B) Cultures of murine (BKS-2) and human (SudHL-4) B lympho-
mas were treated with the SFK inhibitor PP2 (10 μM) or with the inactive control analog, PP3 (10 μM) for 48 hr and then the 
proliferation was measured by [3H]-thymidine uptake. Cultures of murine (C) and human (D) B lymphomas were treated with 
various doses of dasatinib (a dual BCR-ABL and SFK inhibitor) for 48 hr and then the proliferation was measured by [3H]-thy-
midine uptake. The proliferation assay was performed as described in the "Materials and Methods" section. Data points indicate 
percent control response ± S.E. of triplicate cultures from a representative experiment. The percent control response is 
defined as (cpm in the treated group/cpm in the untreated group) × 100. The levels of tritiated thymidine incorporation in the 
untreated groups were between 34,767 and 84,547 cpm.
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46% to 23.4%) cells (data not shown). Since constitutive
BCR signaling is also required for B lymphoma cell pro-
gression from G1 to S phase [3] and Igα and Igβ are
thought to be the direct targets of Src kinase Lyn, the data
are consistent with a role for constitutive Lyn activity in
mediating constitutive B cell signaling to promote lym-
phoma growth. SFK inhibition also caused a modest
increase in sub-G1 cells, indicative of apoptosis. To further
confirm the effect of SFK inhibitors on apoptosis, WEHI-
231 cells were treated with or without 5 μM PP2 for two
days, which increased the apoptotic cells from 8% to 22%
(Fig. 2C). PP2 and dasatinib also caused an increase in
apoptosis in SudHL-4 cells (data not shown). These data
collectively suggested that blocking SFK activity caused G1
- S arrest accompanied by apoptosis in B lymphoma cells.
The active complex of cyclin D/CDK4 targets the retino-
blastoma protein for phosphorylation, allowing the
release of E2F transcription factors to activate G1/S-phase
gene expression. Since blocking SFK caused G1- S arrest for
B lymphoma cells, we asked whether the level of cyclin D2
is affected by SFK inhibition. Treatment of BKS-2 with 10
μM PP2 (G1-S arrest shown in Figure 2B) for 24 hrs signif-
icantly reduced the protein level of cyclin D2 (Fig. 2D),
consistent with SFK inhibition caused G1 - S arrest.
Blocking SFK activity inhibits BCR proximal signaling 
events
Phosphorylation of SFK at the activation loop tyrosine
was completely blocked upon treatment with 10 μM PP2
for all the cell lines tested except OCI-Ly3, which was
reduced 50% but not completely eliminated (Fig. 3A). At
a lower dose of PP1 or PP2 (1 μM), SFK phosphorylation
is only slightly reduced (data not shown). As a control,
phosphorylation of the carboxy-terminal Tyr507 of Lyn
was not inhibited by 10 μM PP2 in SudHL-4 cells (Fig. 3B)
and WEHI-231 cells (data not shown). This suggested that
PP2 only inhibits phosphorylation of the tyrosine at the
activation loop but not phosphorylation of the C-termi-
nal inhibitory tyrosine in SFKs.
In normal B cells, the Src kinase, Lyn phosphorylates Igα
and Igβ to mediate the BCR signaling pathway for B cell
proliferation and differentiation. We hypothesized that
Lyn is deregulated in B lymphoma cells and constitutively
activates BCR signaling pathway to promote B lymphoma
growth. To test that BCR is a direct target of Lyn, Igα was
immunoprecipitated from SudHL-4 cell lysates treated
with or without PP2 and then probed for p-Tyr. Phospho-
rylation of Igα was abrogated upon inhibition of SFK
activity (Fig. 3C); consistent with the notion that Igα is a
downstream target of Lyn. Since Lyn also activates PI3
kinase/AKT pathway by phosphorylating CD19, we asked
whether phosphorylation of CD19 is inhibited upon
blocking SFK activity. CD19 was constitutively phosphor-
ylated in SudHL-4 and BKS-2 cells and was greatly
enhanced by anti-Ig stimulation (anti-Ig data for BKS-2 is
not shown). However, constitutive CD19 phosphoryla-
tion was blocked upon treatment with PP2 but not PP3 or
vehicle.
Phosphorylation of AKT and ERK, but not JNK is blocked 
upon SFK inhibition
Since the early BCR signaling events are inhibited upon
SFK inhibition, we next examined whether the further
downstream pathways are affected as well. In B cells, ERK
Table 1: The IC50 of SFK inhibitors PP1 and PP2 and BCR-Abl kinase/Src kinase inhibitor Dasatinib on a panel of B lymphoma cells of 
human and murine origin.
IC50 PP1( M) PP2 ( M) dasatinib (nM)
Murine lymphoma BKS-2 8.0 7.4 8.3
WEHI-231 4.6 2.8 17.5
CH31 6.1 3.6 -
CH12.Lx 2.5 2.8 7.3
Human lymphoma SudHL-4 1.9 3.1 30
SudHL-6 6.6 5.2 2.9
OCI-Ly-3 19.5 12.6 1400
OCI-Ly-10 3.3 2.0 9.9
BJAB 4.6 3.4 -
The IC50 was determined using the equation derived from a linear regression of the data.
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is a major downstream target that is phosphorylated in
response to BCR signaling [37,49,50]. In BKS-2, CH12.Lx,
OCI-Ly3, OCI-Ly10 lymphoma cells, we observed consti-
tutive ERK activation (Fig. 4A), consistent with constitu-
tively active BCR signaling. Treatment with 10 μM PP2 for
1 hr completely blocked the ERK phosphorylation in
these lymphoma cells except OCI-Ly3, which requires
higher dose of PP2 for complete blocking of SFK activity.
At 1 μM PP1, which is not sufficient for blocking all the
SFK activity, phosphorylation of ERK is not inhibited.
Consistent with this, the proliferation of BKS-2 cells is not
inhibited at this dose (data not shown).
Since ERK MAPK pathway is controlled by Src kinases,
next we asked whether JNK MAPK is also controlled by Src
kinases. PP2 (10 μM) does not affect the phosphorylation
of JNK in CH12, Ly3, BKS-2, and Ly10 (Fig. 4B) and two
other B lymphoma cell lines tested (data not shown), sug-
gesting that JNK pathway is not controlled by Src kinases.
Dasatinib as well did not reduce JNK phosphorylation in
BKS-2 cells.
PP2 and dasatinib induced G1 cell cycle arrest, accompanied by apoptosis in B lymphoma cellsFigure 2
PP2 and dasatinib induced G1 cell cycle arrest, accompanied by apoptosis in B lymphoma cells. Cultures of 0.5 × 
106/ml human SudHL-4 cells (Panel A) or murine BKS-2 (B) were treated with 10 μM PP2 (SFK inhibitor), PP3 (inactive control 
analog), or 100 nM dasatinib (dual BCR-ABL and SFK inhibitor) for 48 hr. Then the cells were spun down and stained with PI 
for cell cycle analysis as described in the Materials and Methods section. (C) 0.5 × 106/ml WEHI-231 cells were treated with 5 
μM PP2 or an equivalent amount of DMSO for 48 hrs. Then the cells were spun down and stained with PI and AnnexinV-FITC 
for apoptosis analysis as described in the Materials and Methods section. (D) BKS-2 cells were treated with or without the indi-
cated amount of PP1 (also a SFK inhibitor) or PP2 for 24 hrs. The cell lysates were probed for cyclin D2, then stripped and re-
probed for β-actin. The ODs for cyclin D2 were normalized to the corresponding bands for β-actin and depicted as a fold 
change over no inhibitor.
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PP2 inhibits the phosphorylation of Tyr396 in the activation loop of the kinase domain of Lyn or equivalent position in other SFKs, leading to a di ruption of early BCR s gnaling eventsFigure 3
PP2 inhibits the phosphorylation of Tyr396 in the activation loop of the kinase domain of Lyn or equivalent 
position in other SFKs, leading to a disruption of early BCR signaling events. (Panel A) A number of B lymphoma 
cells were treated with 10 μM PP2 for 1 hr and then cell lysates were prepared for Western blotting. The blot was first probed 
with p-Src (Y416) antibody, then stripped and re-probed for β-actin. 'Bc' stands for primary B cells. (B) SudHL-4 lymphoma 
cells were treated with or without 10 μM of PP2 for the indicated time points and cell lysates were prepared for Western blot-
ting. The blot was first probed with p-Lyn (Y507) antibody, then stripped and re-probed for total Lyn. The ODs for p-Lyn were 
normalized to total Lyn and depicted as a fold change over 1 hr without PP2. (C) SFK inhibition blocks constitutive phosphor-
ylation of Igα in B lymphoma cells. SudHL-4 cells were treated with or without 10 μM PP2 for 1 hr. Igα was immunoprecipi-
tated from equal amount of cell lysates from both groups and analyzed by Western blotting for p-Tyr. The lysates were also 
probed for Igα as a loading control. The ODs for p-Tyr were normalized to Igα and depicted as a fold change over no PP2 
added. (D) SFK inhibition blocks constitutive phosphorylation of CD19 in B lymphoma cells. BKS-2 and SudHL-4 cells were 
treated as indicated for 4 hr. For a positive control, SudHL-4 cells were treated with 20 μg/ml anti-Ig for 15 min. The cell 
lysates were analyzed by Western blotting with pCD19 antibody. Then the blots were stripped and re-probed with anti-β-actin 
antibody. The ODs for pCD19 were normalized to the corresponding β-actin bands and then for each time point, depicted as 
a fold change over medium only for each panel.
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PI-3 kinase/AKT pathway is an important survival path-
way activated in various cancer cells. In B cells, Lyn phos-
phorylates CD19 to activate PI-3 kinase/AKT pathway in
response to antigen stimulation. Normal splenic B cells
had very low levels of basal AKT phosphorylation which
was enhanced by anti-IgM stimulation (Fig. 4C). In con-
trast, B lymphoma cells have higher levels of AKT phos-
phorylation and treatment with 10 μM PP2 completely
blocked its phosphorylation (Fig. 4C). At a lower dose of
PP2 (1 μM), the AKT phosphorylation is only slightly
inhibited due to insufficient blocking of SFK activity (data
not shown).
Dasatinib inhibits the phosphorylation of SFK and its 
downstream targets
Dasatinib was found to inhibit both BCR-Abl and Src
kinases for Philadelphia chromosome-positive leukemia
cells [51]. Since B lymphoma cells do not express BCR-Abl
kinase, dasatinib is likely to inhibit the B lymphoma
growth by blocking Src kinases. Treatment of BKS-2 cells
with 100 nM dasatinib for 1 hr completely blocked the
phosphorylation of SFK (Fig. 5A). As with PP1 or PP2, the
phosphorylation of AKT and ERK was also completely
blocked by dasatinib. In addition, the transcription factor
Egr-1, which was shown by us to be critical for B lym-
phoma growth [35,37] was reduced 60% upon dasatinib
treatment (Fig. 5A), probably due to the blocking of ERK
activity [37].
Since Lyn is an early component of BCR signaling path-
way, we next asked whether the effect of blocking SFK can
be rescued by directly activating downstream pathways.
Dasatinib (10 nM) potently inhibited the BKS-2 lym-
phoma growth by over 80%. The growth inhibition
caused by dasatinib was partially rescued by PMA, an acti-
vator of PKC (60% rescue) or CpG ODN, an activator of
MAPK and NF-κB (73% rescue) (Fig. 5B).
Bcl-2 family proteins protect B lymphoma cells from SFK 
inhibition induced apoptosis
Although Lyn is important for B lymphoma growth, dif-
ferent B lymphoma cell lines exhibited different sensitiv-
ity to PP2 or dasatinib induced apoptosis. Notably the
human diffuse large B cell lymphoma cell lines such as
SudHL-4 were more resistant to PP2 induced apoptosis
than murine cell lines such as CH12.Lx (Fig. 5C). Since
Bcl-2 translocation is a hallmark for follicular lympho-
mas, we hypothesized that Bcl-2 family proteins have a
role in protecting human diffuse large B cell lymphomas
against SFK inhibition induced apoptosis. Accordingly we
found that all the human diffuse large B cell lymphoma
cells had abundant expression of Bcl-2 and Bcl-xL proteins
compared to two murine immature B lymphoma cell lines
(Fig. 5D). To further establish the correlation between Bcl-
2 protein expression and resistance to SFK inhibitor
induced apoptosis, WEHI-231 stably transfected with Bcl-
xL was compared with parental WEHI-231 for PP2
induced apoptosis. Western blot showed that WEHI-231
stably transfected with Bcl-xL had abundant expression of
Bcl-xL (Fig. 5E). PP2 induced less early apoptosis in WEHI-
231- Bcl-xL cells than the parental WEHI-231 cells (Fig.
5F), suggesting that Bcl-2 family proteins protect B lym-
phoma cells from SFK inhibitor induced apoptosis.
Lyn kinase is over expressed and constitutively active in B 
lymphoma cells
Since Src kinase activity is important for B lymphoma
growth, we next asked which SFKs are preferentially
SFK inhibition blocks the phosphorylation of ERK and AKTFigure 4
SFK inhibition blocks the phosphorylation of ERK and 
AKT. (Panel A) Four B lymphoma cells were treated with or 
without the indicated amount of PP2 for 1 hr. The cell lysates 
were analyzed by Western blotting for p-ERK. The blot was 
stripped and re-probed for total ERK. (B) Four B lymphoma 
cells lines were treated with or without PP2 for 1 hr. The cell 
lysates were analyzed by Western blotting for p-JNK. The 
blots were stripped and re-probed for β-actin. The ODs for 
p-JNK were normalized to the corresponding β-actin bands. 
For each cell line, the ODs are depicted as a fold change over 
no PP2. (C) BKS-2 and Ly10 lymphoma cells were treated 
with or without the indicated amount of PP1 or PP2 for 1 hr. 
As a positive control, normal splenic B cells were treated 
with 20 μg/ml anti-IgM for 15 min. The cell lysates were ana-
lyzed by Western blotting for p-AKT. The blot was stripped 
and re-probed for total AKT. The ODs for p-AKT were nor-
malized to the corresponding bands for total AKT. For each 
cell type, the ODs are depicted as a fold change over no anti-
IgM or PP2.
Molecular Cancer 2009, 8:132 http://www.molecular-cancer.com/content/8/1/132
Page 10 of 15
(page number not for citation purposes)
Dasatinib inhibits constitutive BCR signaling and B lymphoma growth. Bcl-2 and Bcl-xL expression confers resistance to PP2 induced apoptosis in B cell lymphomasFig re 5
Dasatinib inhibits constitutive BCR signaling and B lymphoma growth. Bcl-2 and Bcl-xL expression confers 
resistance to PP2 induced apoptosis in B cell lymphomas. (A) Dasatinib inhibits SFK phosphorylation and phosphoryla-
tion of its downstream targets ERK and AKT and reduces the level of Egr-1 in BKS-2 lymphoma cells. BKS-2 cells were treated 
with or without 100 nM dasatinib for 1 hr. The cell lysates were analyzed by Western blotting for p-SFK, p-ERK and p-AKT. 
The blots were stripped and re-probed for Egr-1, ERK and β-actin. (B) Dasatinib induced growth inhibition can be partially 
overcome by PMA or CpG. BKS-2 cells were treated with DMSO, 10 nM dasatinib, 10 nM dasatinib+10 ng/ml PMA or 10 nM 
dasatinib+1 μg/ml CpG for 48 hrs. The proliferation assay was performed as described in the "Materials and Methods" section. 
Data points indicate percent control response ± S.E. of triplicate cultures from a representative experiment of three independ-
ent experiments. The percent control response is defined as (cpm in dasatinib treated group/cpm in DMSO treated group) × 
100 for dasatinib; (cpm in dasatinib+PMA treated group/cpm in the PMA treated group) × 100 for dasatinib+PMA; (cpm in 
dasatinib+CpG treated group/cpm in CpG treated group) × 100 for dasatinib+CpG. The actual counts for DMSO, PMA and 
CpG treated groups are 16355 ± 1394, 12939 ± 1345, 89504 ± 9159, respectively. (C) SudHL-4 and CH12.Lx cells were 
treated with or without 8 μM PP2 for two days. Early apoptotic cells were detected by flow cytometry with AnnexinV-APC 
and PI staining as described in the "Materials and Methods". (D) Bcl-2 and Bcl-xL protein expression in six B lymphoma cells was 
determined. Cell lysates were analyzed by Western blotting for Bcl-xL and Bcl-2. The blots were stripped and re-probed for β-
actin for loading control. (E) The Bcl-xL expression in WEHI-231 and WEHI-231-Bcl-xL cells (WEHI-231 stably transfected with 
Bcl-xL). Cell lysates were analyzed by Western blotting for Bcl-xL. Then the blot was stripped and re-probed for β-actin for 
loading control. (F) Ectopic expression of Bcl-xL makes WEHI-231 cells more resistant to PP2 induced apoptosis. WEHI-231 
and WEHI-231-Bcl-xL cells were treated with or without 5 μM PP2 for one day. Early apoptotic cells were analyzed by flow 
cytometry with Annexin-V-FITC and PI staining as described.
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expressed in B lymphoma cell lines. Most B lymphoma
cell lines were found to predominantly express two to
three SFKs (Fig. 6A). Lyn and Lck were abundantly
expressed in four and five lymphoma cell lines, respec-
tively. Two cell lines (SudHL-6 and OCI-Ly3) also
expressed Src abundantly and Fgr was expressed in
SudHL-4 and -6. Out of the panel of six SFKs tested,
SudHL-4 expressed the largest number of PTKs. Yes and
Hck were not detected in the six lymphoma cell lines
tested (data not shown). To find which SFK is important
for B lymphoma growth, we hypothesized that active
kinases have phosphorylated tyrosine. As shown in Fig.
6B, Lyn is preferentially phosphorylated in both the lym-
phoma cell lines tested. In addition to Lyn phosphoryla-
tion, OCI-Ly3 also has constitutive phosphorylation of
Src (data not shown). The data suggested that Lyn, in
some cases plus Src, is the active SFK in B lymphoma cells.
To further evaluate the importance of Lyn for B lym-
phoma growth, Lyn specific siRNA was used to examine
the effect of knocking down Lyn expression on B lym-
phoma growth. Western blot showed almost complete
knock-down of Lyn expression in SudHL-4 cells (Fig. 6C).
The expression of Lck protein, another member of the SFK
family, as well as JNK, a MAPK, were unaffected by the Lyn
siRNA treatment. Similarly phosphorylated as well as total
Lyn levels were decreased in siRNA treated SudHL-6 cells
(data not shown). Treatment of three lymphoma cell lines
(including SudHL-4 for which the specific knock-down of
Lyn by siRNA was shown in Fig. 6C) with Lyn specific
siRNA caused a reduction of their growth by 40 - 50%. The
reduction in growth is statistically significant.
Blocking SFK activity inhibits the B lymphoma growth in 
vivo
Since B lymphomas were susceptible to growth arrest
upon treatment with dasatinib, we wanted to test if we
could stop the growth of a B lymphoma in an in vivo lym-
phoma growth model. Twelve mice were divided into two
groups and were injected with BKS-2 tumor cells. From
the next day, seven mice got daily shots of dasatinib
whereas the five control mice got only the vehicle. The
seven dasatinib treated mice showed normal size of
spleens (Fig. 7A, top row) whereas the five mice in the
control group had greatly enlarged spleens due to expan-
sion of tumor cells in the spleen (bottom row). The total
number of cells in the spleen was increased from 92 × 106
per mouse for the drug treated group to 625 × 106 per
mouse for the control group (Fig. 7B). Since a typical
CBA/N (Xid) recipient mouse spleen has 50 × 106 cells,
dasatinib treatment resulted in more than 13 fold reduc-
tion of tumor cells in the spleen.
Lyn is preferentially expressed, phosphorylated, and plays a critical ol  for B mphoma growthFigure 6
Lyn is preferentially expressed, phosphorylated, and 
plays a critical role for B lymphoma growth. (Panel A) 
Lyn and Lck are the predominant SFK expressed in a panel of 
six B lymphoma cell lines. Cell lysates from six representative 
B lymphoma cell lines were analyzed by Western blotting for 
p-SFK and different kinds of SFKs. The blots were stripped 
and re-probed for β-actin for loading control. (B) Lyn is con-
stitutively phosphorylated in CH12.Lx and OCI-Ly10 lym-
phomas. Lck, Lyn or Src were immunoprecipitated from 
equal amount of cell lysates from CH12.Lx and OCI-Ly10 
and probed for p-Tyr by Western blotting. The blots were 
then stripped and re-probed for total SFKs. (C) The Lyn 
siRNA suppressed Lyn expression in SudHL-4 lymphoma 
cells. SudHL-4 cells were transiently transfected with control 
or Lyn specific siRNA as described in the Materials and Meth-
ods section for 48 hrs. Multiple aliquots of cell lysates were 
run on SDS-PAGE and transferred onto PVDF membranes. 
The membranes were cut and separately probed for Lyn, 
Lck, and Jnk. The blots were stripped and re-probed for the 
loading control, β-actin. (D) Blocking Lyn expression by 
siRNA inhibited B lymphoma growth. OCI-Ly10, SudHL-4 
and SudHL-6 lymphoma cell lines were treated with control 
or Lyn specific siRNA as described. Then an equal number of 
cells with the indicated treatment were used to set up the 
proliferation assay as described.
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Discussion
According to the Leukemia & Lymphoma Society http://
www.leukemia-lymphoma.org/hm_lls, as of 2009, an
estimated 600,000 people are living with lymphoma in
the U.S., most of which are NHLs (75%). Lymphoma inci-
dence rose 79% from 1975 - 2005 and survival rates have
not improved much in recent years. Identification of new
drug targets will help improve treatment for lymphoma
patients. Previously, our laboratory reported that constitu-
tive BCR signaling is critical for B lymphoma growth [3].
We showed that expression of BCR co-receptors Ig-α and
Ig-β and activation of the key downstream target Syk are
critical for growth of established B lymphoma cells. As
BCR signaling is dependent on SFKs, we investigated their
role in B lymphoma growth in this study. We observed
that Src kinase activity is constitutively elevated in a
number of primary B lymphomas and diffuse large B lym-
phoma cell lines. Blocking Src kinase activity by specific
pharmacological inhibitors (PP1, PP2 and dasatinib)
inhibited the growth of these B lymphoma cells in a dose
dependent manner. Dasatinib is an orally bioavailable
drug that inhibits both BCR-ABL kinase and Lyn kinase.
Dasatinib was shown to have better efficacy than Imatinib
in treating BCR-ABL(+) CML [42]. In addition, dasatinib
was shown to have activity against a variety of cancer cells
including prostate cancer [52], lung cancers [53,54], head
and neck squamous cell carcinoma [54], and human can-
cers associated with gain-of-function KIT mutations [41]
etc. Here we report that dasatinib inhibits B lymphoma
growth very potently with the IC50 in the nanomolar range
(Table 1). Importantly, we also found that dasatinib
strongly inhibited BKS-2 lymphoma growth in vivo in a
mouse lymphoma model (Fig. 7), making it potential
drug to be tested in combination with current therapies
like R-CHOP [55].
When we examined six B lymphoma cell lines for protein
expression of various SFKs, we found that Lyn and Lck are
over expressed in five B lymphoma cell lines (Fig. 6A). Src
is over expressed in two cell lines. It is a little surprising to
see the expression of Lck in B lymphoma cells, although
Lyn was more predominantly phosphorylated than Lck. It
has now been shown that Lck is expressed in GC and man-
tle cell lymphomas [56,57] but rarely in non-GC B lym-
phomas [58]. The preferential phosphorylation of Lyn
may be due to its association with BCR complex. Elevated
expression and activity of Src have been reported in a vari-
ety of cancers [18,21]. Src was shown to be particularly
important for tumor progression and metastasis [18]. We
found that inhibition of OCI-Ly3 growth requires a much
higher dose of inhibitors than any other lymphoma cell
line tested (Table 1), probably due to over expression and
phosphorylation of both Lyn and Src. Having both active
Lyn and Src, this lymphoma may be a very aggressive
tumor. The functional importance of Lyn was further con-
firmed since targeting Lyn with siRNA resulted in a ~50%
reduction in proliferation for B lymphoma cells tested. A
lack of more complete inhibition may relate to other Src
kinases such as Lck or Src that may be able to substitute for
Lyn's function after Lyn expression is knocked down. Nev-
ertheless, since Lyn is predominantly expressed and con-
stitutively phosphorylated in B lymphomas, Lyn activity
probably accounts for the majority of the constitutive Src
kinase activity seen for B lymphoma cells.
By cell cycle analysis, we found that blocking SFK activity
induces G1-S growth arrest accompanied by apoptosis of
B lymphomas. Consistent with this, we found reduced
expression of cyclin D2 upon SFK inhibition (Fig. 2D).
This is in agreement with a previous report that knocking
down Igα by a siRNA approach caused G1-S growth arrest
for B lymphoma cells [3], suggesting that blocking SFK
activity inhibits constitutive BCR signaling to prevent cell
cycle progression. Consistent with a predominant role of
Lyn in B lymphoma cells, we observed that the BCR prox-
imal signaling events were blocked upon inhibiting SFK
activity, which includes blocking of the tyrosine phospho-
rylation for Igα and CD19. Furthermore, BCR down-
stream pathways such as phosphorylation of AKT and
Dasatinib inhibits B lymphoma growth in vivoFigure 7
Dasatinib inhibits B lymphoma growth in vivo. Dasat-
inib significantly reduced the splenic B lymphoma burden in 
CBA/N (Xid) mice. Female CBA/N (Xid) mice were injected 
intravenously with 7 × 106 BKS-2 B lymphoma cells on day 0. 
From day 1, mice were injected intraperitoneally either with 
drug (dasatinib) or vehicle (1 × PBS, 10% DMSO) everyday 
for 14 days. (A) A comparison of the spleen sizes between 
drug and vehicle treated lymphoma bearing mice. (B) The 
average counts of total splenic cells between drug and vehicle 
treated lymphoma bearing mice.
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ERK, but not JNK were blocked upon SFK inhibition. Egr-
1, a zinc finger transcription factor, shown to be impor-
tant for B lymphoma growth [35] was also down regu-
lated upon SFK inhibition. The data support an active role
for Lyn kinase in mediating constitutive BCR signaling for
lymphoma survival (CD19/PI3K/AKT pathway) and
growth (ERK MAPK pathway). The SFK induced growth
inhibition can be partially overcome by treating the cells
with PMA or unmethylated CpG ODN. Since PMA
directly activates the BCR downstream kinase, Protein
Kinase C (PKC), hence ERK and Egr-1 [37], this suggests
that the active PKC-ERK pathway can partially circumvent
the blocking of BCR signaling caused by SFK inhibition.
CpG activates Toll like receptor 9 mediated signaling
pathways. CpG can rescue immature B lymphoma cells
from BCR-mediated apoptosis by inducing a sustained
activation of NF-κB, and subsequent expression of Bcl-xL
and c-Myc [59,60] and an up regulation of Egr-1 [61].
In general, the human B lymphoma cell lines required
higher doses of SFK inhibitors than murine B lymphoma
cells to induce growth inhibition. There was very little
apoptosis in the SFK inhibitor treated human B lympho-
mas. We showed that this could be related to increased
expression of anti-apoptotic proteins Bcl-2 and Bcl-xL by
the human B lymphomas compared to the murine lym-
phomas. Furthermore, constitutive expression of Bcl-xL
made the WEHI-231 cell line less susceptible to SFK
induced apoptosis.
Our data suggest that the constitutive BCR signaling in B
lymphoma cells [3] is likely due to constitutive activation
of Lyn, the upstream enzyme required for tyrosine phos-
phorylation of Igα and Igβ. Our studies are in general
agreement with a recent report by Yang et al. [30] about
the effects of dasatinib on lymphoma growth in vitro.
They compared dasatinib to Imatinib to support the con-
cept that SFK but not other tyrosine kinases are important
for lymphoma growth. However, proteomic approaches
have demonstrated that dasatinib can affect other PTKs
like BTK, Csk, as well as other Ser/Thr kinases like p38α
MAPK [62,63]. Therefore, our study used siRNA to specif-
ically knock down Lyn and thus demonstrated Lyn is
required for lymphoma growth. Furthermore, we were
able to demonstrate dasatinib efficacy in an in vivo lym-
phoma model. The obvious question is: Why is Lyn kinase
constitutively active in B lymphoma cells? One possibility
is that Lyn is mutated in B lymphoma cells, which may be
unlikely, since Lyn is active in a number of murine and
human lymphoma cells. Another possibility is that Lyn is
constitutively active due to the association of Lyn with
lipid rafts that don't contain the negative regulator Csk in
B lymphoma cells [64]. In normal B cells, Lyn is only tran-
siently activated in response to BCR engagement by anti-
gen. Singh et al showed that BCR engagement led to a Ca2+
dependent, rapid production of reactive oxygen species
(ROS), in particular H2O2 [65]. The ROS in turn led to a
rapid and transient inhibition of protein tyrosine phos-
phatase (PTP) activity associated with the BCR due to the
oxidation of the critical cysteine in the active site of PTP
[66-69] and a transient increase in Lyn kinase activity
[65]. Thus the extent of PTP oxidation determines the acti-
vation status of Lyn. In the light of this observation, and
the data indicating a strong correlation between ROS and
lymphomagenesis [68,69], it is conceivable that B lym-
phoma cells have a higher level of production of ROS than
the normal B cells and the high level of ROS directly inac-
tivates the PTPs, which causes phosphorylation and con-
stitutive activation of Lyn. In support of this, we observed
a higher level of global tyrosine phosphorylation in B
lymphoma cells compared to the normal B cells (data not
shown). It is interesting to note that phosphorylation on
Tyr507 of Lyn did not keep Lyn inactive and Lyn is still
phosphorylated on Tyr396. It may be that over expression
of Lyn kinase promotes their aggregation and leads to
autophosphorylation on Tyr396 first and an inactivation
of SHP-1 by ROS keeps this phosphorylation stable. Once
Lyn is phosphorylated on Tyr396, it may be less affected
by the phosphorylation on Tyr507 due to an inactivation
of CD45.
The complexity of the role of Lyn in B cells versus B lym-
phomas (negative and positive roles) is reminiscent of its
negative role in normal myeloid cell development [11]
and its positive role for the growth of chronic myeloid
leukemia cells, where Lyn inhibitors are already being
tested in clinic [70]. Similarly acute myeloid leukemia
cells express constitutively active Lyn and their growth is
inhibited by PP2 [71].
Overall, our studies suggest a model in which constitutive
Lyn kinase activity phosphorylates Igα and Igβ to mediate
the constitutive BCR signaling for B lymphoma survival
and growth. Our data also suggest that like other types of
cancers, B lymphomas are heterogeneous. In addition to
having the constitutively active Lyn activity and constitu-
tive BCR signaling, some lymphomas may have over
expression of Bcl-2 anti-apoptotic proteins due to chro-
mosomal translocation of BCL2 gene into the Ig loci. For
those B lymphomas with Bcl-2 expression, small Src
kinase inhibitors such as dasatinib in combination with
Bcl-2 inhibitors such as ABT-737 [72] may be more effec-
tive than any single treatment.
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